BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19151774)

  • 1. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia.
    Seifert H; Mohr B; Thiede C; Oelschlägel U; Schäkel U; Illmer T; Soucek S; Ehninger G; Schaich M;
    Leukemia; 2009 Apr; 23(4):656-63. PubMed ID: 19151774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
    Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
    Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
    Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
    Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
    Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
    Schnittger S; Bacher U; Kern W; Alpermann T; Haferlach C; Haferlach T
    Leukemia; 2011 Aug; 25(8):1297-304. PubMed ID: 21537333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
    Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
    Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
    J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.